UKCA vs CE mark for medical software: what actually differs

UKCA and CE marking started from the same directive-based rules. Since the EU MDR replaced the directives in the EU, the requirements behind the two marks have diverged — most visibly for the classification of software. This guide compares the requirements side by side. If you want to know which route to use to get onto the Great Britain market — CE recognition timelines, the UK Responsible Person, MHRA registration and the October 2026 plan for indefinite CE recognition — read our guide to UK market access for medical software.

Lizaveta Dabrynskaya
Lizaveta Dabrynskaya
Founder & Regulatory Consultant · 13+ years

Short answer

CE marking rests on the EU MDR, with certificates from EU Notified Bodies; UKCA rests on the UK Medical Devices Regulations 2002, still based on the old EU directives, with certificates from UK approved bodies. For software the biggest difference is classification: EU MDR Rule 11 puts most decision-support software in class IIa or higher, while UK MDR 2002 has no equivalent rule. Most of the technical file can serve both marks, but you need a classification analysis under each framework. CE marked devices can be placed on the GB market until 30 June 2030, and the government plans indefinite recognition; a UK Responsible Person and MHRA registration are needed either way.

1. Why UKCA and CE now rest on different rules

When the UK left the EU, the UKCA (UK Conformity Assessed) mark was introduced for Great Britain. For medical devices, the governing law is the UK Medical Devices Regulations 2002 (UK MDR 2002), which gave effect in UK law to the old EU directives (MDD, AIMDD and IVDD). The UKCA requirements are still based on the annexes of those directives, as modified for GB.

The EU, meanwhile, replaced the directives with the EU MDR (Regulation (EU) 2017/745) and the IVDR. So the two marks now sit on different generations of rules. The UK plans to narrow the gap: MHRA has said its planned pre-market regulations will bring the essential requirements into closer alignment with the EU, introduce UDI and change the classification of several device types — but those regulations are not yet in force. Recognition runs one way only: GB recognises CE marking (see below), while the EU does not recognise UKCA.

Northern Ireland exception

The EU MDR has applied in Northern Ireland since 26 May 2021. Products placed on the Northern Ireland market need CE marking (with the UKNI indication where a UK notified body performed the assessment); UKCA is not recognised there. If your distribution includes NI, your CE obligations remain regardless of your UKCA status.

2. Requirements side by side

The table below covers the differences that matter most for medical software companies.

Area CE marking (EU MDR) UKCA (UK MDR 2002)
Legal basis Regulation (EU) 2017/745 UK MDR 2002 (as amended), based on the former EU directives
Classification of software Annex VIII Rule 11: software that provides information used for diagnostic or therapeutic decisions is at least Class IIa Directive-based rules with no software-specific rule; much standalone software ends up in Class I
Conformity assessment body EU notified body designated under the MDR (52 at the time of the Commission's February 2026 survey) UK approved body; UK approved bodies cannot carry out CE assessments
When a third party is needed Class IIa, IIb, III — and sterile, measuring or reusable surgical aspects of Class I Class IIa, IIb, III — and sterile or measuring aspects of Class I
Representative for foreign manufacturers EU authorised representative UK Responsible Person — required for all non-UK manufacturers placing devices in GB, including with CE marking
Registration and UDI EUDAMED actor, UDI/device and certificate registration mandatory since 28 May 2026 (with a transition for devices already on the market) MHRA device registration before placing on the GB market; UDI not yet required — planned in the pre-market regulations
Labelling CE marking with the notified body number where one is involved; UDI UKCA mark with the approved body number where one is involved; UKRP name and address on labelling, outer packaging or IFU
Post-market surveillance MDR Articles 83–86: PMS plan, PMCF, PSUR at least every two years (Class IIa) or annually (Class IIb/III); vigilance reported to national authorities Strengthened GB PMS requirements in force since 16 June 2025; serious incidents reported to the MHRA; apply to CE marked devices in GB too
AI-specific rules EU AI Act high-risk requirements for AI medical devices from 2 August 2028 No AI-specific device legislation; AI devices are regulated under UK MDR 2002 like other software
Recognition in the other market CE marking recognised in GB — until 30 June 2030 for EU MDR devices under current law; the government intends to make this indefinite UKCA not recognised in the EU, EEA or Northern Ireland

3. Software classification and AI — the differences that matter most

Classification of standalone software

EU MDR Rule 11 moved most decision-support and diagnostic software to Class IIa or higher, with a well-developed interpretation framework in MDCG guidance. UK MDR 2002 has no equivalent rule, so the same product can sit in a lower class in GB — often Class I, which can be self-declared under UKCA. The government's October 2026 consultation response confirms that, while GB and EU classification rules are largely aligned, some differences exist; the planned pre-market regulations will change the classification of several device types, but the published documents do not detail changes for software.

If your software sits near a classification boundary, run separate classification analyses under EU MDR Rule 11 and UK MDR 2002 — do not assume the result will be the same. This is part of our regulatory strategy and classification work.

AI and machine learning

Under CE marking, AI-based SaMD must comply with the EU MDR and, for the high-risk requirements, the EU AI Act. After Regulation (EU) 2026/1744, those requirements apply to AI medical devices from 2 August 2028, with a single set of technical documentation assessed by your notified body as part of the MDR conformity assessment. See our EU AI Act guide for medical software.

Under UKCA, AI medical devices are regulated under UK MDR 2002 like other software; there is no UK counterpart to the EU AI Act's binding high-risk requirements. The short-term documentation burden for UKCA is therefore lower — but UK guidance can change without the formal legislative process that applies to EU regulations.

Do not treat lower burden as lower risk

A less prescriptive UK framework for AI does not mean your product can be less rigorously validated. In our experience, approved bodies look for evidence of responsible AI development even where specific documentation is not codified in law, and thin AI validation evidence draws questions in any assessment.

4. Do you need both marks?

Usually not. For the EU and Northern Ireland you need CE marking. For Great Britain you need either CE marking recognised in GB or UKCA — with a UK Responsible Person, MHRA registration and GB post-market surveillance in both cases. Under current law, EU MDR CE marking is recognised in GB until 30 June 2030, and on 21 October 2026 the government announced its intention to recognise EU MDR/IVDR CE marked devices indefinitely; that still needs legislation, which it plans to make before 30 June 2028.

So the question is less "do I need both?" than "is a UK-controlled route worth having?". For most EU-first SaMD companies, CE marking plus the GB obligations is enough. UKCA becomes interesting when your software classifies lower in GB, when the UK is your first market, or when you want a GB route that does not depend on EU certification.

The efficiency case if you do want both

If you pursue both marks, plan for it from the start. Your ISO 13485 QMS, IEC 62304 software life-cycle documentation, risk management and clinical evidence can serve both certifications, with a separate classification analysis, UK approved body assessment and UK-specific labelling and registration on top. Running both processes in parallel rather than one after the other usually saves calendar time.

5. UKCA first: when it makes sense

There are legitimate scenarios where pursuing UKCA before CE marking is the right commercial decision:

  • NHS-first go-to-market strategy. If your first customers are NHS trusts or UK private providers and EU expansion comes later, UKCA can allow earlier revenue while your EU MDR technical file matures.
  • Lower classification in the UK. Where your software is Class I under UK MDR 2002 but Class IIa or higher under EU MDR Rule 11, UKCA can be a faster path to first market validation while your notified body process proceeds in parallel.

UKCA-only is not a long-term strategy for most companies: the UKCA mark is not recognised in the EU, EEA or Northern Ireland, and the EU remains the larger market for most European SaMD companies.

6. Practical next steps

CE marking (EU MDR)

Plan for long notified body timelines. In the Commission's notified body survey (data as of 28 February 2026), most notified bodies reported 13–18 months from signed written agreement to certificate for combined QMS and product certificates, and a large share reported 19–24 months or more. Our guide to a realistic EU MDR timeline for software breaks this down.

UKCA

For a Class I product under UK MDR 2002, UKCA is a self-declaration — the work is the technical documentation, the UKRP and MHRA registration. For Class IIa and above, the timeline depends on the UK approved body you choose and the completeness of your documentation; ask candidate bodies for their current lead times.

Recommended approach

  • Build your QMS to ISO 13485 with both markets in mind from the start — this avoids painful retrofitting later.
  • Run classification analyses under both EU MDR Rule 11 and UK MDR 2002 before committing to a conformity assessment route.
  • Select your EU notified body (and, if you pursue UKCA, your UK approved body) early — both have application queues.
  • Plan EUDAMED registration (EU) and MHRA device registration with your UK Responsible Person (GB) as parallel workstreams.
  • If your SaMD uses AI, build your AI Act Annex IV documentation into the technical file from the start — the high-risk requirements apply to AI medical devices from 2 August 2028, and retrofitting takes longer than building in.
Bottom line

UKCA and CE marking now rest on different rules — most visibly for software classification — and the EU does not recognise UKCA. GB, by contrast, recognises CE marking and intends to continue doing so indefinitely, so for many SaMD companies CE marking plus the GB obligations (UKRP, MHRA registration, GB post-market surveillance) is the efficient route. Decide on UKCA deliberately, based on your classification and your market sequence.

Official sources & references

Related guides

Frequently asked questions

Yes. Under current law, devices compliant with the EU MDR can be placed on the Great Britain market until 30 June 2030; devices still under the old MDD until the sooner of certificate expiry or 30 June 2028. On 21 October 2026 the government announced its intention to recognise EU MDR/IVDR CE marked devices indefinitely — this needs legislation, planned before 30 June 2028. You still need a UK Responsible Person (if based outside the UK), MHRA registration and GB post-market surveillance. Northern Ireland applies the EU MDR, so CE marking is required there. For the full market-access picture, see our UK market access guide.
CE marking rests on the EU MDR, with certificates issued by EU notified bodies; UKCA rests on UK MDR 2002, which is based on the former EU directives, with certificates from UK approved bodies. The biggest practical difference for software is classification: EU MDR Rule 11 puts most decision-support software in Class IIa or higher, while UK MDR 2002 has no equivalent rule. The standards you use (ISO 13485, IEC 62304, ISO 14971) are largely the same, but the conformity assessments are separate legal processes, and UK approved bodies cannot issue CE certificates.
If you are based outside the UK, yes — and not only for UKCA. Non-UK manufacturers placing devices on the Great Britain market, including CE marked devices, must appoint a UK Responsible Person (UKRP). The UKRP registers your devices with the MHRA, keeps the technical documentation available and cooperates with the MHRA. Devices that are not registered cannot lawfully be placed on the GB market. For UKCA marked devices, the UKRP's name and address must appear on the labelling, outer packaging or IFU.
Largely, yes — most of the content (QMS, software life-cycle records, risk management, clinical evidence) can serve both. You still need a classification analysis under each framework, UK-specific references and labelling, and — for Class IIa and above under UK MDR 2002 — a UK approved body alongside your EU notified body, each following its own procedure. Some certification groups operate both an EU notified body and a UK approved body, which can make coordination easier, but the certificates remain separate.
MHRA has said a pre-market statutory instrument will introduce UDI, change the classification of several device types (the 2026 documents name IVDs and implantable devices), bring the essential requirements closer to the EU, and create a framework for international reliance. MHRA said it would follow in 2026; the October 2026 government response still describes it as upcoming, and confirms that the UKCA mark will remain available. Devices already holding UKCA marking may need documentation updates once the new requirements apply, so watch for the statutory instrument.
Lizaveta Dabrynskaya
Lizaveta Dabrynskaya
Founder, TrustedTraceMed · Regulatory and quality consultant for medical device software

Regulatory and quality consultant for medical device software, with 13+ years in the healthcare domain. Built an ISO 13485 QMS from scratch for a Class IIa SaMD and worked on EU MDR, UKCA and Malaysia MDA submissions. Independent consultant, not a Notified Body.

Planning UKCA, CE marking, or both?

In a free 30-minute call we look at your product and markets and which route makes sense for each.

Request a free call →
No commitment · Fixed-fee proposals · Reply within 1 business day